XXXIIIrd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 12, 2020 | VIRTUAL CONFERENCE

Final Programme

www.ehmsg.org
XXXIIIrd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 12, 2020 | VIRTUAL CONFERENCE
### Awardees of the Marshall and Warren Medal

2020 Hazel Mitchell, Sydney, Australia  
2019 Guillermo Perez-Perez, New York, NY, United States  
2018 Kenneth McColl, Glasgow, United Kingdom  
2017 Jean-Charles Delchier, France  
2016 Ken Sugano, Shimotsuke, Japan  
2015 Heidi-Ingrid Maaroos, Tartu, Estonia  
2014 Manfred Kist, Freiburg, Germany  
2013 Masahiro Asaka, Sapporo, Japan  
2012 Richard Hunt, Hamilton, ON, Canada  
2011 Samy Cadranel, Brussels, Belgium  
2010 Reinhold W. Stockbrügger, Maastricht, The Netherlands  
2009 Pelayo Correa, Nashville, TN, United States  
2008 Timo Kosunen, Helsinki, Finland  
2007 Mike Dixon, Leeds, United Kingdom  
2006 Barry Marshall, Perth, Australia & Stanislav Konturek, Cracow, Poland

### NEXT EHMSG WORKSHOP

September 16 - 18, 2021  
Belgrade, Serbia
Welcoming address by the President of the European Helicobacter and Microbiota Study Group
Prof. Dr. Georgina Hold

Dear Colleagues, Dear Friends,

It is my great pleasure, on behalf of the European Helicobacter and Microbiota Study group (EHMSG) to welcome you to our 2020 VIRTUAL conference. Just as EHMSG has evolved over the years as a dynamic and forward-thinking society, this year we have also had to be innovative and creative in terms of delivering our annual conference, in light of the current global pandemic.

We are delighted to welcome you to a fantastic programme of world-class speakers covering many aspects of Helicobacter and microbiota current research. In addition to the one-day speaker programme, there are e-posters to view and also a number of pre-recorded talks which are available on-demand.

I can’t finish this welcome address without thanking the EHMSG group and the team at the Vienna Medical Academy who together have worked tirelessly to make this virtual conference a reality. I am also hugely grateful to our sponsors who have continued to support us and demonstrate their commitment to EHMSG.

The EHMSG 2020 meeting promises to be scientifically inspiring, providing the latest developments from the Helicobacter and Microbiota field.

I look forward to seeing you online!

Ceud Mile Fáilte

Georgina Hold
President of the EHMSG
European Helicobacter & Microbiota Study Group EHMSG

President of the EHMSG
Georgina Hold, Australia

Members and International Scientific Committee
Leif P. Andersen, Denmark
Lars Engstrand, Sweden
Antonio Gasbarrini, Italy
Javier P. Gisbert, Spain
Ernst Kuipers, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Colm A. O’Morain, Ireland
Mirjana Rajilic-Stovanovic, Serbia
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece
Annemieke Smet, Belgium
Herbert Tilg, Austria

Honorary Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Corresponding Fellows
Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chung-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Emeritus Members
Anthony Axon, United Kingdom
Michel A.L. Deltenre, Belgium
Bram Flahou, Belgium
Giovanni Gasbarrini, Italy
Alexander M. Hirschl, Austria
Pierre Michetti, Switzerland
José M. Pajares Garcia, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal (†)
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Corresponding Fellows
Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chung-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Organizing Office
Core Agency
Scientific and Administrative Secretariat
Vienna Medical Academy
Catherine Tomek
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 18
Fax: +43 1 405 13 83 918
Email: workshop@ehmsg.org

Workshops of the EHMSG

Bordeaux (1988)
Ulm (1989)
Toledo (1990)
Bologna (1991)
Dublin (1992)
Brussels (1993)
Houston (1994)
Edinburgh (1995)
Copenhagen (1996)
Lisbon (1997)
Budapest (1998)
Helsinki (1999)
Rome (2000)
Strasbourg (2001)
Athens (2002)
Vienna (2004)
Copenhagen (2005)
Wroclaw (2006)
Istanbul (2007)
Riga (2008)
Porto (2009)
Rotterdam (2010)
Dublin (2011)
Ljubljana (2012)
Madrid (2013)
Rome (2014)
Nicosia (2015)
Magdeburg (2016)
Bordeaux (2017)
Kaunas (2018)
Innsbruck (2019)
Virtual Event (2020)
Belgrade (2021)
Glasgow (2022)
Antwerp (2023)
SAVE THE DATE

XXXIV Workshop of the European Helicobacter and Microbiota Study Group

www.ehmsg.org

SEPTEMBER 16 - 18, 2021
BELGRADE | SERBIA
PROGRAMME SATURDAY, SEPTEMBER 12, 2020

08.15 – 08.30 Welcome and Introduction
Georgina Hold, Sydney, Australia

08.30 – 08.50 I - Introductory Lecture
Moderator: Georgina Hold
A tribute to George Sachs: pH & Hp revisited, then and now
Richard Hunt, Hamilton, ON, Canada

08.50 – 09.50 II - Gastric Epithelium Homeostasis in Health and Disease
Moderators: Georgina Hold, José Machado
Unexpected role of TLR5: Flagellin-independent but T4SS-dependent activation control Helicobacter pylori infections
Steffen Backert, Erlangen, Germany

09.10 – 09.30 Molecular mechanisms of Helicobacter pylori disruption of epithelial integrity
Ceu Figueiredo, Porto, Portugal

09.30 09.50 Gastric organoids as a tool to study Helicobacter infection
Francesco Boccellato, Oxford, UK

09.50 – 10.00 10 minutes break

10.00 – 12.30 III - Symposium: H. pylori diagnostics & treatment - I
Moderators: Javier Gisbert, Colm O’Morain
“Test and Treat” strategy with UBT: a cost effective strategy for the management of H. pylori infection in UK
Mark Pritchard, Liverpool, UK
Rationale behind UBT H. pylori screening and eradication therapy to reduce the risk of Upper GI bleeding in patients with myocardial Infarction. Insights from the HELP-PILOT study
Magnus Bäck, Stockholm, Sweden

10.40 – 11.00 Acid suppression – how much is needed?
Takahisa Furuta, Hamamatsu, Japan

11.00 – 11.20 Renaissance reviewed - Bismuth still needed?
Peter Malfertheiner, Magdeburg, Germany

11.20 – 11.30 10 minutes break

10.00 – 12.30 III - Symposium: H. pylori diagnostics & treatment - II
Moderators: Francis Mégraud, Peter Malfertheiner
Overcoming antibiotic resistance – the Korean experience
Ji Yong Ahn, Ulsan, Korea
Guidelines are good – adherence is better
Pali Hungin, Durham, UK

12.10 – 12.30 Management of H. pylori infection based on global/regional guidelines
Seung Joo Kang, Seoul, Korea
12.30 – 12.35  IV - Presentation of the Journal “Microbiota in Health and Disease”
Moderators: Francis Mégraud, Peter Malfertheiner
Francesco Franceschi, Rome, Italy

12.35 – 12.45  V - Awarding of the Marshall & Warren Medal to Hazel Mitchell, Australia
Moderator: Georgina Hold
Hazel Mitchell, Sydney, Australia

12.45 – 14.40  EHMSG Quiz
Josbert Keller, Leiden, The Netherlands

Lunch Break
Visit the virtual exhibition spaces of our sponsors and view the On-Demand Talks & e-Posters

14.40 – 15.40  VII - Gut Microbiota in Health and Disease
Moderators: Mirjana Rajilic-Stojanovic, Lars Engstand

14.40 – 15.00  Microbial Therapeutics: Are we there yet? Clinicians perspective
Tariq Iqbal, Birmingham, UK

15.00 – 15.20  Using the microbiome to turn liquid diet into solid food. The CD-TREAT diet for treating Crohn’s disease
Richard Hansen, Glasgow, UK

15.20 – 15.40  Microbial transplant – what are the challenges?
Josbert Keller, Leiden, The Netherlands

15.40 – 15.50  10 minutes break

15.50 – 16.50  VIII - EHMSG Guidelines initiative in microbiota handling
Moderators: Annemieke Smet, Josbert Keller

15.50 – 16.10  The challenge of microbiota testing
Antonio Gasbarrini, Rome, Italy

16.10 – 16.30  Requirements for optimal testing
Mirjana Rajilic-Stojanovic, Belgrade, Serbia

16.30 – 16.50  Clinical relevance of microbiota signature
Gianluca Ianiro, Rome, Italy

16.50 – 17.00  10 minutes break

17.00 – 19.00  IX - Symposium: Gastric Cancer – Early detection and prevention 2020
Moderators: Marcis Leja, Theodore Rokkas

17.00 – 17.20  H. pylori in the stomach – factors contributing to its dominance
Richard Peek, Nashville, TN, USA

17.20 – 17.40  Current epidemiology and gastric cancer patterns
Constanza Camargo, Rockville, USA

17.40 – 18.00  Population-based screening of gastric cancer
Jin-Young Park, Lyon, France
18.00 – 18.30  
*H. pylori* screen-and-treat: Pro & Con - Talk  
18.00 – 18.15  Con:  Anthony O’Connor, Dublin, Ireland  
18.15 – 18.30  Pro:  Jan Bornschein, Oxford, UK  

18.30 – 19.00  
Preneoplastic conditions - Tandem Talk  
18.30 – 18.45  is it time for molecular risk prediction?  Marnix Jansen, London, UK  
18.45 – 19.00  how good is endoscopy?  Alexander Link, Magdeburg, Germany  

19.00 – 19.15  
X - Closing Session  
Moderators: Antonio Gasbarrini, Ari Ristimäki  

19.00 – 19.10  
Poster Awards  
Ari Ristimäki, Helsinki, Finland  

19.10 – 19.15  
Presentation of the EHMSG Workshop 2021 in Belgrade  
Mirjana Rajilic-Stojanovic, Belgrade, Serbia
ON-DEMAND TALKS

The Gut Microbiota – the latest branch of medicine
Juozas Kupcinskas, Kaunas, Lithuania

Harnessing the microbiome – Virome Potential
Indrani Mukhopadhy, Aberdeen, UK

Practical Considerations for understanding the Microbiome
Lars Engstrand, Solna, Sweden

Microbiome Analysis – Bioinformatics Perspective
Chris Quince, Warwick, UK

Birth and Early Life
Omry Koren, Safed, Israel

Microbes and Brain Function
Daniel Wall, Glasgow, UK

Atopic disease
Reetta Satokari, Helsinki, Finland

Cancer
Patricia Lepage, Jouy en Josas, France

The Microbiota in Obesity Associated Disease
Marie Joossens, Gent, Belgium

The Microbiota and Liver Disease
Debbie Shawcross, London, UK

PPI treatment and its impact on the GI microbiota – any clinical relevance?
Christian Schulz, Munich, Germany

Microbial manipulation in IBS
Magdy El-Salhy, Bergen, Norway

Microbial manipulation in IBD
Patrizia Kump, Graz, Austria
Electronic Poster Round 1: Diagnosis of Helicobacter infection

EP1.01
"Test-and-Treat" strategy with urea breath test: a cost-effective approach for the management of Helicobacter pylori-related dyspepsia and the prevention of peptic ulcer in the United Kingdom-Results of the Hp-Breath initiative
David PRITCHARD, Liverpool, United Kingdom

EP1.02
Comparative estimation of results of the new selective rapid urease test and detection of H. pylori in stool: a pilot study
Natalia Baryshnikova, St-Petersburg, Russian Federation

EP1.03
Screening for Helicobacter pylori infection and Clarithromycin resistance using real-time polymerase chain reaction
Mila Kovacheva-Slavova, Sofia, Bulgaria

EP1.04
Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding- The results of a network meta-analysis
Nóra Vörhendi, Pécs, Hungary

EP1.05
Helicobacter pylori screening in patients with acute myocardial infarction
Robin Hofmann, Stockholm, Sweden

EP1.06
Diagnosis of Helicobacter pylori infection in the elderly by immunochromatographic assay-based stool antigen test
Yingjie Han, Beijing, China

EP1.07
Implementation of the program of the Scientific Society of Gastroenterologists of Russia „Physicians without helicobacteriosis” in Chita
Elena Luzina, Chita, Russian Federation

EP1.08
Helicobacter pylori and mast cells in the mucous membrane of the stomach
Natalya Samodurova, Voronezh, Russian Federation

EP1.09
Immunomorphological aspects of evaluating the interaction of mast cells and Helicobacter pylori in the stomach mucous
Natalya Samodurova, Voronezh, Russian Federation

Electronic Poster Round 2: Treatment of Helicobacter infection

EP2.01
Quality assessment of meta-analyses: probiotics and eradication of Helicobacter pylori infection
György Buzás, Budapest, Hungary

EP2.02
Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: a systematic review and meta-analysis
Doron Boltin, Petah Tikva, Israel

EP2.03
European registry on Helicobacter pylori management (Hp-EuReg): first-line therapy in Israel
Doron Boltin, Petah Tikva, Israel

EP2.04
Eradication rate of Helicobacter pylori infection in Chinese duodenal ulcer patients treated with Vonoprazan 20 mg versus Lansoprazole 30mg with bismuth containing quadruple therapy
Jiangbin Wang, Changchun, China

EP2.05
Helicobacter pylori eradication first- and second-line regimens prescriptions and effectiveness in Lithuania: Analysis From the European Registry on H. pylori Management (Hp-EuReg)
Laimas Jonaitis, Kaunas, Lithuania
EP2.06
*Helicobacter pylori* eradication treatment in Lithuania during 2013-2019: trend analysis of the European Registry on *H. pylori* management (Hp-EuReg)
Paulius Jonaitis, KAUNAS, Lithuania

EP2.07
Difference in the *Helicobacter pylori* eradication rates according to the time of treatment start in patients with peptic ulcer bleeding
Hak Kim, Seoul, Korea, Republic of

EP2.08
Current trend in the *Helicobacter pylori* eradication rates of first-line sequential and concomitant therapies in Korea: A nationwide multicenter retrospective study over the 10 years
Byung-Wook Kim, Incheon, Korea, Republic of

EP2.09
Comparing efficacy of *Helicobacter pylori* eradication regimens: Bismuth containing quintet therapy vs. moxifloxacin based sequential therapy as first-line eradication regimen
Yoo Jin Kim, Bundang, Korea, Republic of

EP2.10
First-line *H. pylori* eradication therapy in Europe: Results from 24,882 cases of the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.11
Room for improvement in the treatment of *Helicobacter pylori* infection: lessons from the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.12
European Registry on *H. pylori* Management (Hp-EuReg): empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020
Javier Gisbert, Madrid, Spain

EP2.13
European Registry on *H. pylori* Management (Hp-EuReg): Analysis of empirical second-line treatments in Europe
Javier Gisbert, Madrid, Spain

EP2.14
A deadly hug: chitosan microspheres functionalized with MSI-78A antimicrobial peptide kill *Helicobacter pylori*
Diana Fonseca, Universidade do Porto, Portugal

EP2.15
Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.16
European Registry on *H. pylori* Management (Hp-EuReg): Experience with single capsule bismuth quadruple therapy in 3,439 patients
Javier Gisbert, Madrid, Spain

EP2.17
Safety of the treatment of *H. pylori* infection: experience from the European Registry on *H. pylori* Management (Hp-EuReg) on 22,000 patients
Javier Gisbert, Madrid, Spain

EP2.18
Bismuth quadruple regimen with tetracycline or doxycycline versus Pylera® as third-line rescue therapy for *H. pylori* infection: A prospective multicenter analysis of the European Registry on *Helicobacter pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain
EP2.19
European Registry on *H. pylori* Management (Hp-EuReg): Clinical phenotypes through machine learning of first-line treated patients in Spain during the period 2013-2018
Javier Gisbert, Madrid, Spain

EP2.20
Empirical versus susceptibility-guided treatment of *Helicobacter pylori* infection: a meta-analysis
Javier Gisbert, Madrid, Spain

EP2.21
Real-world comparative effects of three-in-one single capsule bismuth quadruple therapy vs. non-bismuth quadruple concomitant therapy: Interim analysis of the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.22
Antibiotic resistance trends of *Helicobacter pylori* naïve patients in the period 2013-2019: analysis of the European Registry on *H. pylori* Management (Hp-Eu-Reg)
Javier Gisbert, Madrid, Spain

EP2.23
Tailored therapy based on clarithromycin resistance is effective for the first-line therapy of *Helicobacter pylori*
Sang Gon Moon, Seoul, Korea, Republic of

EP2.24
*Helicobacter pylori* antibiotic resistance: data from the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.25
Impact of *Helicobacter pylori* clarithromycin resistance on the treatment effectiveness: data of the European Registry on *H. pylori* Management (Hp-EuReg)
Javier Gisbert, Madrid, Spain

EP2.26
Trends in the effectiveness of eradication therapy in Russia
Dmitry Bordin, Moscow, Russian Federation

EP2.27
The comparison of side effects and effectiveness of standard triple therapy with clarithromycin and alternative high-dose amoxicillin / bismuth therapy in eradication of *H. pylori*
Alise Lielause, Riga, Latvia

EP2.28
The effects of Eupatilin of NSAID-gastropathy associated with *H. pylori*
Igor Skrypnyk, Poltava, Ukraine

EP2.29
Excellent performance of 2-weeks tailored triple therapy in *H. pylori* infected children: Interim results of the new EuroPedHp Registry
Thu Giang Le Thi, Munich, Germany

EP2.30
Myricetin as a natural compound sensitizing *H. pylori* to antibiotics
Paweł Krzyżek, Wrocław, Poland

EP2.31
Counteracting *Helicobacter pylori* using drug-free nanostructured lipid carriers (NLC)
Rute Chitas, Porto, Portugal

EP2.32
Effectiveness of first-line *H. pylori* eradication therapy according to the daily statin-use: analysis of the European Registry on *H. pylori* Management (Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.33
Effectiveness of first-line *H. pylori* eradication treatments in Spain: results from the European Registry on *H. pylori* management
(Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.34
Effectiveness of second-line *H. pylori* eradication treatments in Spain: results from the European Registry on *H. pylori* management (Hp-EuReg)
Maria Caldas, Madrid, Spain

EP2.35
Population study on the prevalence and antimicrobial resistance of *Helicobacter pylori* in West Flanders - Belgium.
Alexander Vanden Bulcke, Leuven, Belgium

EP2.36
European registry on *H. pylori* management (Hp-EuReg): analysis of 1,782 empirical rescue therapies on third and subsequent lines
Diego Burgos-Santamaría, Madrid, Spain

EP2.37
Autoprobiotics in treatment of *Helicobacter pylori* gastritis
Elena Ermolenko, Saint-Petersburg, Russian Federation

EP2.38
Antibiotics susceptibility testing increases *Helicobacter pylori* eradication rates in dyspeptic patients from Egypt: a randomized controlled trial
Mohamed Alboraie, Darrasah, Egypt

EP2.39
Nifuratel in the eradication of *Helicobacter pylori* infection in adults: results of a randomized comparative clinical trial
Natalia Dekhnich, Smolensk, Russian Federation

EP2.40
Toxic effects of bismuth on *Helicobacter pylori* associated with the intra-gastric acidity: a transmission electron microscopy study
Yi-Chia Lee, Taipei, Taiwan

EP2.41
A real-life study assessing the efficacy of single capsule Bismuth quadruple therapy supplemented with probiotics for *H. pylori* eradication in patients naïve to treatment in a high clarithromycin resistance area
K. Priadko, Naples, Italy

EP2.42
Modified bismuth quadruple therapy with low dose metronidazole as first-line therapy for *Helicobacter pylori* infection
Gyu Young Pih, Seoul, Korea, Republic of

EP2.43
*Helicobacter pylori* resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community
Robin Bruyndonckx, Antwerp, Belgium

EP2.44
Antibiotic Resistance Breakers to counteract the multidrug-resistance in *Helicobacter pylori*
Silvia Di Lodovico, Chieti, Italy

EP2.45
The effectiveness of various anti Helicobacter therapy regimens in Ukraine
Yana Nikiforova, Kharkiv, Ukraine

EP2.46
Potential role of new Resveratrol derivatives for the management of drug resistant *Helicobacter pylori* infection
Mara Di Giulio, CHIETI, Italy

EP2.47
Evaluation of antimicrobial activity against *Helicobacter pylori* and phytochemical analysis of extracts from Passiflora and Ilex species
Johan Castañeda, Bogota, Colombia
EP2.48 Empiric versus Clarithromycin-Resistance-Guided Therapy for *Helicobacter pylori* based on Polymerase Chain Reaction Results in Patients with Gastric Neoplasms or Gastric MALT Lymphoma: a Randomized Controlled Trial
Jue Lie Kim, Seoul, Korea, Republic of

EP2.49 Antioxidant and anti-inflammatory properties of a grape seed extracts against *Helicobacter pylori* infection
Teresa Alarcón, Madrid, Spain

EP2.50 Effects of temperature on the growth and metronidazole resistance in *Helicobacter pylori*
Meiliang Gong, Beijing, China

EP2.51 Amoxicillin secretion by gastric mucosa in patients with atrophic and nonatrophic gastritis undergoing *H. pylori* eradication therapy
Anastasiya Sablina, Saint-Petersburg, Russian Federation

EP2.52 The chimeric protein CTB-multiHp: immunological features and the ability to inhibit *Helicobacter pylori* activities.
Beatriz Meza, La Paz, Mexico

Electronic Poster Round 3: Gastric cancer

EP3.01 Application of gold nanoparticles and metal oxide sensors for non-invasive detection of gastric cancer
Linda Mezmale, Riga, Latvia

EP3.02 Identification of volatile organic compounds emitted by gastric juice
Linda Mezmale, Riga, Latvia

EP3.03 *Helicobacter pylori* CagA hijacks cortactin to control host cell migration via Vav2-mediated small GTPase Rac1 activation
Steffen Backert, Erlangen, Germany

EP3.04 The repeat regions of *Helicobacter pylori* VirB10-ortholog CagY can bind and activate toll-like receptor 5
Steffen Backert, Erlangen, Germany

EP3.05 Overexpression of toll-like receptor 5 in *H. pylori* infected patients with or without neoplasia
Steffen Backert, Erlangen, Germany

EP3.06 *H. pylori* chronic gastritis: OLGA and OLGIM evaluation and serum biomarkers for risk assessment of gastric cancer development in Brazilian patients
Luiz Coelho, BELO HORIZONTE, Brazil

EP3.07 Evaluation of the nonspecific immunity in patients with gastric cancer with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.08 The role of non-specific monocytic phagocytes in the progression of gastric cancer associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.09 Features of lipid peroxidation and antioxidant protection in gastric cancer associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP3.10 Peculiarities of glutathione antioxidant protection functioning in gastric cancer associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation
EP3.11
Leisha Nolen, Anchorage, United States

EP3.13
Gastric cancer risk factors due to life style
Elizaveta Ageeva, Simferopol, Russian Federation

EP3.14
Aberrant MUC13 expression as prognostic marker for gastric cancer
Baptiste Oosterlinck, Antwerp, Belgium

EP3.15
Cost-effectiveness of Helicobacter pylori screening and eradication to prevent stomach cancer in Spain
Teresa Alarcón, Madrid, Spain

EP3.16
In vitro profiling of volatil organic compounds released and consumed by CLS-145 and HGC-27 gastric cell lines
Linda Mezmale, Riga, Latvia

EP3.18
Endoscopic biopsy sampling during gastroscopy - discrepancies across Europe
Jan Bornschein, Oxford, United Kingdom

EP3.19
Impact of Helicobacter pylori infection and its virulence factor CagA on DNA damage repair machinery
Eleftherios Kontizas, Athens, Greece

EP3.20
The role of lactate in gastric carcinogenesis
Karla Vinasco-Pacheco, Sydney, Australia

EP3.21
ER stress and inflammation via autophagy influence Helicobacter pylori-related gastric cancer
Isidora Simovic, Sydney, Australia

EP3.22
Leukaemia Inhibitory Factor signalling for targeting cancer stem cells in gastric adenocarcinoma
Lornella Seeneevassen, Bordeaux, France

EP3.23
Cell-free DNA somatic alterations in plasma of gastric cancer patients: mutational spectra, association with tumor size and survival
Greta Streleckiene, Kaunas, Lithuania

EP3.24
Induction of precancerous phenotype of normal gastric epithelial cells after their long-term incubation with supernatant from Helicobacter pylori-infected cancer-associated fibroblasts in vitro. Involvement of transforming growth factor beta and its recep
Tomasz Brzozowski, Cracow, Poland

EP3.25
Microbial abundance of H. pylori assessed by high-throughput sequencing and prognosis of gastric cancer patients
Alexander Link, Magdeburg, Germany

EP3.26
Helicobacter pylori and Epstein-Barr virus co-infection in Greek patients with gastric malignancies
Beatriz Martinez-Gonzalez, Athens, Greece

EP3.27
Increasing trend of gastroesophageal junction in the primary site of endoscopic resected gastric cancers
Younghee Choe, Seoul, Korea, Republic of
Electronic Poster Round 4: Helicobacter infection - pathogenesis and host response

EP4.01
Important role of integrin receptors in controlling the AGS cell elongation/hummingbird phenotype by *Helicobacter pylori* CagA
Steffen Backert, Erlangen, Germany

EP4.02
The actin-binding protein cortactin is required for efficient AGS cell elongation by *H. pylori* CagA, but not for vacuolization and apoptosis by VacA
Steffen Backert, Erlangen, Germany

EP4.03
Type IV secretion of *Helicobacter pylori* CagA and ADP-heptose into oral epithelial cell lines
Steffen Backert, Erlangen, Germany

EP4.04
The role of pro-inflammatory and anti-inflammatory cytokines in the development of chronic atrophic gastritis with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.05
Immunoglobulins in chronic gastritis and chronic atrophic gastritis with *H. pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.06
Features of the functioning of monocytes in chronic gastritis associated with *Helicobacter pylori- infection*
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.07
Role of monocytes during chronic atrophic gastritis associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.08
Features of lipid peroxidation and antioxidant protection in chronic atrophic gastritis associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.09
The role of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis associated with *Helicobacter pylori* infection
Olga Smirnova, Krasnoyarsk, Russian Federation

EP4.10
Indicators of proliferation and apoptosis of gastric epithelial cells in the indigenous inhabitants of the Republic of Tyva with *Helicobacter pylori*-positive duodenal ulcer
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP4.11
Immunophenotype of cell infiltrate of the gastric mucosa lamina propria in indigenous inhabitants of Khakassia with *Helicobacter pylori*-positive duodenal ulcer
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP4.12
Upregulation of intercellular cell adhesion molecule-1 in endothelial cells exposed to *Helicobacter pylori* outer membrane vesicles
JUNG MOGG KIM, Seoul, Korea, Republic of

EP4.13
*Helicobacter pylori* infection affects nitric oxide system in patients with chronic antral gastritis and diabetes mellitus type 2
Igor Skrypnyk, Poltava, Ukraine

EP4.14
ACTIVE FORMS OF OXYGEN IN MONOCYTE CULTURE UNDER HIGH DISSEMINATION WITH *HELCOBACTER PYLORI*
Irina Litvinova, Krasnoyarsk, Russian Federation
EP4.15
*Helicobacter pylori* alters expression of Notch pathway components in gastric epithelial cells and macrophages in a cell type specific manner.
Rebecca FitzGerald, Dublin, Ireland

EP4.16
Presence of Matrix Metalloproteinase-9-positive Neutrophil Extracellular Traps (NETs) in gastric biopsies of *H. pylori* infected patients
Elissavet Michailou, Athens, Greece

EP4.17
Virulence gene cagA of *Helicobacter pylori* and severe esogastroduodenal diseases: is there a relationship?
Mônica Barbosa, Goiânia, Brazil

EP4.18
Clinical Treatment Outcomes and Prognosis of Gastric MALToma : A Single Center Experience
Won Shik Kim, Seoul, Korea, Republic of

EP4.19
*Helicobacter pylori* dupA virulence gene: risk factor or protector of gastropathies?
Mônica Barbosa, Goiânia, Brazil

EP4.20
Contribution of *Helicobacter pylori* to foam cell formation in experimental atherosclerosis
Agnieszka Krupa, Lodz, Poland

EP4.21
Modulation of Nrf2-mediated antioxidant response after infection with *Helicobacter pylori* may contribute to gastric cancer
Océane MARTIN, Bordeaux, France

EP4.22
Modulation of *Helicobacter pylori* adhesion to gastric epithelial cells by BCGOnko vaccine mycobacteria
Weronika Gonciarz, Lodz, Poland

EP4.23
Induction of autoantibodies in response to infection with CagA-positive *Helicobacter pylori*
Weronika Gonciarz, Lodz, Poland

**Electronic Poster Round 5: Epidemiology**

EP5.01
Prevalence and genetic features of drug resistant *Helicobacter pylori* strains from Zhengzhou
Chuan Liu, zhengzhou, China

EP5.02
Prevalence of *Helicobacter pylori* infection in north-eastern Romania- data from a tertiary care center
Elena Popovici, Iasi, Romania

EP5.03
Changes in the prevalence of *Helicobacter pylori* over last 25 years among Lithuanian medical students
Laimas Jonaitis, KAUNAS, Lithuania

EP5.04
Evaluation of dyspeptic symptoms in *Helicobacter pylori*-positive and negative students of Lithuanian University of Health Sciences
Laimas Jonaitis, Kaunas, Lithuania

EP5.05
The prevalence of CagA *Helicobacter pylori* in children of the Mongoloid population of Siberia
Tamara Polivanova, Krasnoyarsk, Russian Federation

EP5.06
The influence of parental education on the prevalence of *Helicobacter pylori* in rural children
Tamara Polivanova, Krasnoyarsk, Russian Federation
E-POSTER PRESENTATIONS

EP5.07
Trends in the prevalence of Helicobacter pylori in Russia
Dmitry Bordin, Moscow, Russian Federation

EP5.08
Time trends in acute upper gastrointestinal bleeding in Serbian adult population
Vladimir Milivojevic, Belgrade, Serbia

EP5.09
Relationship of Helicobacter pylori infection to lifestyle, sociodemographic and economic profile in dyspeptic patients
Mônica Barbosa, Goiânia, Brazil

EP5.10
Retrospective analysis of the H. pylori eradication rates in Crimean population.
Valeriy Kryvy, Simferopol, Russian Federation

EP5.11
Helicobacter pylori reinfection rates in Crimean population: follow-up study
Valeriy Kryvy, Simferopol, Russian Federation

Electronic Poster Round 6: Microbiology and genomics of Helicobacter

EP6.01
Changes in the fluoroquinolone resistance of Helicobacter pylori over a 14-year period and discovery of a novel mutation in DNA gyrase: a single center study in Korea
Jae Kim, Seoul, Korea, Republic of

EP6.02
Clarithromycin resistance of Helicobacter pylori strains isolated in St. Petersburg, Russia
Alena Svarval, Saint Petersburg, Russian Federation

EP6.03
The genomic polymorphism of clinical strains of H. pylori isolated in St. Petersburg, Russia.
Alena Svarval, Saint Petersburg, Russian Federation

EP6.04
Helicobacter pylori resistance, treatment outcome and point mutation analysis based on molecular testing in Serbian adult population
Vladimir Milivojevic, Belgrade, Serbia

EP6.05
Clarithromycin resistance is more common among less virulent Helicobacter pylori strains - Data from an Irish centre.
Rebecca FitzGerald, Dublin, Ireland

EP6.06
Pathway of focal adhesion and its relevant circRNAs and IncRNAs are involved with perianal Crohn’s disease.
Shi-xue Dai, Guangzhou, China

EP6.07
Comparison in vitro of activity of various macrolides against Helicobacter pylori
Natalia Dekhnich, Smolensk, Russian Federation

EP6.08
East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide
Hong Li, Chengdu, China

EP6.09
The role of two PDZ domains in HtrA from Helicobacter pylori in the protein quality control system
Urszula Zarzecka, Gdansk, Poland

EP6.10
New Helicobacter pylori prophage phylogenetic population from Colombian strains
Angela Muñoz, Bogotá, Colombia
E-POSTER PRESENTATIONS

EP6.11
Frequency of Helicobacter pylori cagA, dupA and vacA genotypes and their association with severity of gastric pathologies in clinical patients in midwestern Brazil
Mônica Barbosa, Goiânia, Brazil

EP6.12
Comparative genomic analysis of novel Helicobacter pylori strains isolated from domestic cats with gastritis reveals unique genetic profile that may contribute to colonization and pathogenicity in feline hosts
Anthony Mannion, Cambridge, United States

EP6.13
Current worldwide population structure of Helicobacter pylori
Roberto Torres, Shanghai, China

EP6.14
Muller’s ratchet-like effect in Helicobacter pylori, a highly recombining bacterial species.
Elise Tourette, Shanghai, China

EP6.15
Characterization of Helicobacter pylori Infection in the upper gastrointestinal tract of Twins.
Alexander Link, Magdeburg, Germany

Electronic Poster Round 7: Helicobacter and extragastroduodenal disease

EP7.01
A potential association between Helicobacter pylori infection and metabolic syndrome-related nonalcoholic fatty liver disease severity
Jannis Kountouras, Thessaloniki, Macedonia, Greece

EP7.02
Impact of Helicobacter pylori eradication on the risk of incident nonalcoholic fatty liver disease
Hyuk Lee, Seoul, Korea, Republic of

EP7.03
Cohort study of Helicobacter pylori infection and the risk of Incident osteoporosis in women
Hyuk Lee, Seoul, Korea, Republic of

EP7.04
The prevalence of Helicobacter pylori and the structure of the gastric mucosa in elderly patients with GERD
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

EP7.05
Clinical implication of Helicobacter pylori infection for eosinophilic esophagitis : A single center experience
Eun Ji Lee, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of

EP7.06
The features of Helicobacter pylori infection and gastrointestinal manifestations of allergy in children of Eastern Siberia
Anna Barilo, Krasnoyarsk, Russian Federation

EP7.07
H. pylori prevalence in individuals with allergic disease in the Latvian population
Jelizaveta Aleksejeva, Riga, Latvia

EP7.08
Helicobacter pylori outer membrane vesicles induce astrocyte reactivity
Esteban Palacios, Santiago, Chile

EP7.09
Strain specific pathological changes in the liver of mice infected with Helicobacter pylori (H. pylori).
Sadia Khalid, tallinn, Estonia
**EP7.10**
*Helicobacter pylory*-induced inflammatory response mediates invadosome formation and emergence of hybrid epithelial mesenchymal phenotype in infected hepatocytes
Olga Smirnova, Tallinn, Estonia

**EP7.11**
Role of Helicobacters in Idiopathic Parkinsonism: a systematic review
Rosalind Tucker, London, United Kingdom

**EP7.12**
*H. pylori* Associated to Irritable Bowel Syndrome (IBS)
Adriana Barrios, Quetzaltenango, Guatemala

**Electronic Poster Round 8: Paediatric conditions**

**EP8.01**
The peculiarities of stomach mucosa in *Helicobacter pylori* schoolchildren
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.02**
Cytokines in *Helicobacter pylori*-associated gastritis in children with a family predisposition to gastric pathology
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.03**
Cytokeratins CK20, CK7 in assessing the severity of lesions of the gastric mucosa in schoolchildren with *Helicobacter pylori* associated gastritis
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.04**
Levels of IL-2, IL-4 with erosive and ulcerative lesions of the gastroduodenal zone associated with *Helicobacter pylori* in schoolchildren with pathology of the digestive tract in parents
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.05**
Is CDX2 in children an immunohistochemical marker for the adverse course of gastritis?
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.06**
The relationship of blood leptin with *Helicobacter pylori* in children
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.07**
Chronic *Helicobacter Pylori* infection in Siberian adolescents with gastroesophageal reflux disease (GERD)
Sergey Tereshchenko, Krasnoyarsk, Russian Federation

**EP8.08**
Efficacy of standard triple therapy in the eradication of *Helicobacter Pylori* in Siberian children: a single centre experience of treatment outcomes
Sergey Tereshchenko, Krasnoyarsk, Russian Federation

**EP8.09**
Effect of Helicobacter pylori on the formation of erosive-ulcerative lesions of the gastroduodenal zone, GERD and their associative relationship
Tamara Polivanova, Krasnoyarsk, Russian Federation

**EP8.10**
Application of liquid probiotic concentrate for gastroduodenitis of Helicobacter etiology in children
Olga Obukhova, Novosibirsk, Russian Federation

**EP8.11**
*H. pylori* infection in symptomatic Mexican children
Omaha Celestino-Perez, Mexico City, Mexico
Electronic Poster Round 9: Upper GI microbiota in health and disease

EP9.01
Treatment of non-erosive reflux disease and change of esophageal microbiome: A prospective multicenter study
Sang Kil Lee, Seoul, Korea, Republic of

EP9.02
Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multicenter study
Chan Hyuk Park, Guri, Korea, Republic of

EP9.03
Helicobacter pylori and the possible probiotic Lactobacillus salivarius co-exist in Estonian gastric biopsy sample
Kaisa Roots, Tallinn, Estonia

Electronic Poster Round 10: Gut microbiota and non-intestinal disease

EP10.01
Effect of fecal microbiota transplantation on clearance of carbapenem resistant enterobacteraceae
yong woon Shin, Incheon, Korea, Republic of

EP10.02
Gut microbiota depending on the atopic dermatitis severity in children in Eastern Siberia
Anna Barilo, Krasnoyarsk, Russian Federation

EP10.03
watercress and the gut
kyle stewart, newton abbot, devon, United Kingdom

Electronic Poster Round 11: Microbiota and intestinal disease

EP11.01
Trimebutine maleate as a multidimensional-antibacterial agent against functional dyspepsia: a prospective multicenter randomized, double-blind controlled trial
Jannis Kountouras, Thessaloniki, Greece

EP11.02
Gut microbiota disorders in patients with inflammatory bowel diseases
Natalia Baryshnikova, St-Petersburg, Russian Federation

EP11.03
Comparison of glucose and lactulose breath test results for detecting small intestinal bacterial overgrowth
Arta DENINA, Riga, Latvia

EP11.04
THE PREVALENCE OF HELICOBACTER PYLORI AND PROTOZOAN INVASIONS AND THE IMPACT ON THE PERFORMANCE OF ENZYMATIC DIGESTION
Guzel Isaeva, Kazan, Russian Federation

EP11.05
Fecal Microbiota Transplantation as treatment for recurrent Clostridiodes difficile infection in patients with Inflammatory Bowel Disease: Experiences of the Netherlands Donor Feces Bank
Emilie van Lingen, Leiden, Netherlands

EP11.06
A CONSIDERABLE RATE OF COVID-19 GI SYMPTOMS IS ASSOCIATED WITH ANTIMICROBIAL THERAPY: FINDINGS FROM A LARGE WESTERN PROSPECTIVE COHORT
Serena Porcari, Rome, Italy
Electronic Poster Round 12: Microbiota and cancer

EP12.01
The clinical outcomes of treatment for low grade gastric mucosa associated lymphoid tissue lymphoma unresponsive to 
*Helicobacter Pylori* eradication
Sunah Suk, Seoul, Korea, Republic of

Electronic Poster Round 13: Gut microbiota manipulation

EP13.01
Initial experience of the first Brazilian stool bank with fecal microbiota transplantation for recurrent Clostridioides difficile infection
Luiz Gonzaga Coelho, BELO HORIZONTE, Brazil

EP13.02
Impact of high fat diets with different content of unsaturated fatty acids on hydrogen gas generation by the gut microbiota in rats
Anastasia Ivanova, Moscow, Russian Federation

Electronic Poster Round 14: Microbiota detection and analyses

EP14.01
Circulating blood microbiome signatures in patients with liver cirrhosis: association between clinical parameters, circulating taxa and inflammatory cytokines
Rolandas Gedgaudas, Kaunas, Lithuania

EP14.02
Laboratory assessment of a device prototype for Methane and Hydrogen breath testing
Elena Kolomina, St. Petersburg, Russian Federation

EP14.03
Multiparameter flow cytometric enumeration of the commercial probiotic products
Katarzyna Sielatycka, Szczecin, Poland

EP14.04
In-depth comparison of different platforms for high throughput sequencing microbiome analyses of gastric mucosa
Alexander Link, Magdeburg, Germany
LIVE SESSIONS

Session Structure for Live Presentations
All sessions include pre-recordings as well as a live component. We want to make sure to retain as much human interaction as possible.
Prior to the session, all lectures are recorded and uploaded to our system. They need to be of an exact length (as indicated in your information mailing) to ensure smooth development of the session.
At the scheduled timeslot of the session, the chairperson of the session will open the session and introduce the speakers.
Then the recording of the first lecture will be played. At all times there is a live-chat available, where all participants can contribute to the session or ask questions which will be monitored by the moderator.
After each lecture, there is some time reserved for a discussion with the chairperson. Lecturers and chairpersons therefore need to be online at the scheduled timeslot. They will discuss questions from the audience or further details of the session. This is the same procedure for all lectures.

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

Speaking Time
The chairpersons of live sessions will be strict in allowing no more than the time allotted to discussions following the pre-recorded presentations.
Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.

ON-DEMAND TALKS & e-POSTER PRESENTATIONS
On-Demand Talks and e-Poster presentations can be viewed by participants “on-demand”, which means that individual presentations do not have dedicated times at which they can be viewed – they can be viewed at any time. Authors of e-Poster presentations can be contacted via a messaging system on the conference platform as of September 12, 2020.

AVAILABILITY OF PRESENTATIONS DURING AND AFTER THE CONFERENCE
All on-demand and e-poster presentations will be available (for registered participants only) on the virtual platform on the day of the conference and remain there for review until one month after the conference.
All live presentations will be moved to the on-demand section after September 12, 2020 and remain available there for review (for registered participants only) until one month after the conference.
Microbiota in Health and Disease, the official journal of the European Helicobacter and Microbiota Study Group – EHMSG, is focused on all issues related to the role of microbiota in maintaining health or promoting diseases, not only confined to the GI tract.

Its scope ranges from publishing papers on novelties in basic science, translational research, clinical trials and new therapeutic options, in order to supply international researchers with a valuable platform of discussion of challenges and opportunities in the field of microbiota.

You are kindly invited to submit your valuable paper completely
FREE OF CHARGE

For submissions please visit the website: https://www.microbiotajournal.com
Acknowledgements

The organisers gratefully acknowledge the support of the following institutions and companies:
GENERAL INFORMATION

In alphabetical order.

Breaks and Lunch Break
During the session breaks we invite you to visit our sponsors virtual exhibition spaces as well as the on-demand and e-Poster presentations.

Cancellations and Refunds
Registration fees may be refunded if written cancellation has been received as follows:
– until August 16, 2020: full refund
– between August 17 – September 8, 2020: 50% refund
– from September 9, 2020: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering to EHMSG 2020, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Refunds will be made after September 12, 2020

Certificate of Attendance
Confirmations of attendance will be issued to all registered participants and sent via e-mail.

CME Credits
The “XXXIIIrd International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer” taking place virtually was granted a total of 7 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Functionality of the virtual platform
The conference organiser’s subcontractors provide a high level of availability of their network, cannot however give any guarantee that their network will operate without any interruptions or malfunctions.

No assurances or guarantees can be given about the availability, quality, operation or support services for data traffic, on the networks, or lines of the participant’s Internet provider.

The conference organiser is not liable if the provision of the services is interrupted, partially restricted, or impossible as a result of force majeure. Force majeure is for example considered natural phenomena of significant intensity (avalanches, floods, etc.), conflicts, terrorism, strikes, unexpected official restrictions, power cuts, computer viruses, worms, Trojan horses etc.

Language
The official language of the workshop is English (no simultaneous translation).

Liability
In registering for the EHMSG 2020 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Virtual Conference and Virtual Exhibition on September 12, 2020
08.15 – 19.15 hrs CEST
All Live Talks, On-Demand Talks and e-Poster presentations will be available in the On-Demand Section after the conference as of September 13, 2020 until October 12, 2020.
PRESENTATIONS

All presenters are requested to upload their pre-recorded presentations on the virtual platform until September 3, 2020. **Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.**

A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

REGISTRATION DETAILS

**Registration Fees** (one fee applies for all participants)

| Regular Participants | EUR 100.– |

Payment of Registration fees may be made either by Credit Card (Diners Club, Mastercard and Visa) at any time, or by bank transfer until September 1, 2020.

**What is covered by the registration fee?**

- Access through the virtual platform to all scientific sessions
- Access through the virtual platform to all recorded sessions until October 12, 2020
- Access through the virtual platform to all company exhibition spaces

**Twitter**

The European Helicobacter and Microbiota Study Group is present on Twitter @ehmsg

We invite you to follow us on Twitter, engage and discuss with your colleagues.
Detect and confirm eradication of an active *H. pylori* infection in just minutes

**Curian® HpSA®**

Compact, sample-to-result GI assay platform

- **Simple** sample prep
- **Easy**,** standardized workflow** - less than 1 minute hands-on time
- **Flexible** testing options - batch or load-and-go option
- Fluorescent technology **improves performance, removes subjectivity**

Visit Curian® HpSA® virtually
www.meridianbioscience.com/meetcurian
New Instruments Generations in Breath Test Analysis

**TIME FOR CHANGE**

**IR-FORCE 200 Android**

**IR-FORCE 200 Fancy**

**IR-FORCE 300 Plus**
Helicobacter Test INFAI®

One of the most used $^{13}$C-urea breath tests for the diagnosis of Hp-infections worldwide

- New line of INFAI packaging and serialization according the EU’s Falsified Medicines Directive
- More than 6.8 million Helicobacter Test INFAI performed worldwide
- Registered in more than 40 countries worldwide
- First approved Hp test for children from the ages of 3 to 11
- Modified Hp test for patients taking PPIs (REFEX)
- Cost-effective CliniPac Basic for hospital and GPs use

INFAI GmbH
Riehler Str. 36
50668 Cologne
Germany

Phone: +49 221 880 44-3
Fax: +49 221 880 44-55
Email: mail@infai.de, info@infai.co.uk
Web: www.infai.de, www.infai.co.uk